The latest price target for Perspective Therapeutics (AMEX:CATX) was reported by Cantor Fitzgerald on September 10, 2024. The analyst firm set a price target for $0.00 expecting CATX to fall to within 12 months (a possible -100.00% downside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Perspective Therapeutics (AMEX:CATX) was provided by Cantor Fitzgerald, and Perspective Therapeutics reiterated their overweight rating.

There is no last upgrade for Perspective Therapeutics

There is no last downgrade for Perspective Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Perspective Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Perspective Therapeutics was filed on September 10, 2024 so you should expect the next rating to be made available sometime around September 10, 2025.

While ratings are subjective and will change, the latest Perspective Therapeutics (CATX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Perspective Therapeutics (CATX) is trading at is $12.99, which is out of the analyst’s predicted range.